肺癌一直是中国癌症中发病率和死亡率最高的病种，肺部小结节是绝大部分该疾病早期的表现形式。中 国患有肺结节人数约为1.5亿人，超过95%的肺结节为良性。目前，针对肺结节和肺癌的检测诊断技 术，要么检测率低，要么无法作为早期诊断筛查手段。 试剂盒通过多家医院测试，共纳入1463例肺结节患者。其中，肺癌病例794例，早期肺癌样本占比达 58.19%。数据显示，试剂盒对早期肺癌的检测灵敏度超过65%，准确度显著优于传统肿瘤标志物。"对 于低剂量螺旋CT表现不典型的小结节，辅以该试剂盒检测，诊断准确率可提升至85%以上。"胡海表 示。 据悉，试剂盒预计在春节后正式面向市场，有望为"健康中国2030"癌症早筛战略提供关键支撑。（记者 江耘 实习生姚佩琦 通讯员刘岚轩） "解决肺结节良恶性鉴别诊断，是突破肺癌早诊难题，降低肺癌死亡率的关键。"胡海说。 团队从2016年起聚焦肺癌早诊痛点，并锁定肿瘤自身抗体检测技术。可是人体生物系统极为复杂，要精 准找到肺癌特异性标志物如同"大海捞针"。为此，团队利用百万级癌症组织文库和多模态高通量筛选技 术，结合合成生物学方法，重组表达400余种肺癌早期关键蛋白，并通过自主开发的液态悬浮芯 ...

据悉，试剂盒预计在春节后正式面向市场，有望为"健康中国2030"癌症早筛战略提供关键支撑。 "解决肺结节良恶性鉴别诊断，是突破肺癌早诊难题，降低肺癌死亡率的关键。"胡海说。 26日，记者从中国科学院杭州医学研究所获悉，该所研究员、该所附属肿瘤医院学术副院长胡海科 研团队主导研发的13种肺癌相关抗体检测试剂盒（流式荧光免疫法），正式获得国家药监局三类医疗器 械注册证，成为全球首个针对CT发现肺结节（尤其是小结节）良恶性鉴别的辅助诊断试剂盒，并有望 显著提升肺癌早期诊断率。 团队从2016年起聚焦肺癌早诊痛点，并锁定肿瘤自身抗体检测技术。可是人体生物系统极为复杂， 要精准找到肺癌特异性标志物如同"大海捞针"。为此，团队利用百万级癌症组织文库和多模态高通量筛 选技术，结合合成生物学方法，重组表达400余种肺癌早期关键蛋白，并通过自主开发的液态悬浮芯片 技术和人工智能算法，筛选出13种诊断性能最优的标志物组合。其中8种为全新组合的标志物，远超现 有临床应用水平。"这项技术能捕捉早期肺癌的'分子信号'，在癌细胞数量极少、病情隐匿时就能发出 预警，非常适合早筛早诊。"胡海说。 肺癌一直是中国癌症中发病率和死亡率最高的病种 ...

Core Points - The article emphasizes the importance of early screening and standardized clinical diagnosis for lung cancer, which is the most prevalent and deadly malignant tumor in China [1] - It highlights the typical symptoms of early-stage lung cancer and identifies high-risk groups [2] Group 1: Lung Cancer Overview - Lung cancer originates from bronchial mucosa or glands and is mainly classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being more common and having a relatively better prognosis [1] - Early-stage lung cancer often presents with subtle symptoms, making it difficult to detect [1] Group 2: Symptoms and Detection - Typical symptoms of lung cancer include persistent cough, sputum production, blood-streaked sputum, and dry cough without phlegm, which may not respond to common cough medications [1] - Atypical symptoms such as hoarseness, back pain, or leg pain may indicate lung cancer with bone metastasis, particularly in cases of small cell lung cancer [1] Group 3: High-Risk Groups - Individuals aged 50 to 80 years are considered high-risk for lung cancer, with smoking history being a significant risk factor, particularly for those with a smoking history of 20 pack-years [2] - Other risk factors include pre-existing lung conditions like chronic obstructive pulmonary disease (COPD) or tuberculosis, exposure to secondhand smoke, and occupational hazards involving asbestos, dust, and metal particles [2] - Family history of lung cancer also increases the likelihood of developing the disease [2]

Core Insights - The article highlights the significant achievements of China in the field of new drug development, attributing these successes to the 2015 reform of the drug review and approval system, which has integrated China's clinical research into global multi-center studies [1] - The 2025 European Society for Medical Oncology (ESMO) conference showcased numerous Chinese experts and their research, indicating a growing international collaboration and interest in Chinese innovative pharmaceuticals [1] - The 2025 Sino-European Academic Forum on Thoracic Diseases emphasizes the importance of cross-cultural collaboration and the sharing of clinical practices and innovations between China and Europe [2] Group 1: Drug Development and Innovation - The 2015 drug policy reform has been pivotal in enhancing China's capabilities in clinical research and drug development, leading to significant advancements in treatment options for various diseases [1] - Chinese innovative pharmaceutical companies are increasingly engaging in international licensing collaborations, with high-quality data disclosure being a critical foundation for these partnerships [1] Group 2: Academic Forum Highlights - The 2025 Sino-European Academic Forum focuses on three main themes: local innovation and clinical practice, global advancements and technological breakthroughs, and cross-cultural collaboration in future medicine [2] - Prominent Chinese scholars presented on topics such as vascular disease treatment strategies and precision lung cancer therapy, showcasing China's achievements in clinical practice and research translation [2] Group 3: Clinical Practices and Technologies - The forum included discussions on the differences in lung cancer early screening practices between China and European countries, highlighting China's proactive approach in early diagnosis [5] - The use of surgical robots in thoracic surgery was emphasized as a means to enhance precision and reduce complications, with potential for remote medical applications and AI-driven surgical procedures in the future [6] - The integration of traditional Chinese medicine with modern oncology practices was explored, focusing on improving patient quality of life and addressing adverse reactions to targeted therapies [6]